Registered outcomes19

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 19 of 19

List	Outcome	Time frame	Description
Primary	Pulmonary perfusion was assessed using both pulse wave and saline bolus EIT at PEEP levels of 5 and 15 cmH₂O.	Under both PEEP 5 cmH₂O and PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	At a PEEP of 5 cmH₂O, pulse wave EIT data were recorded for 3 minutes. Subsequently, during an inspiratory or expiratory hold, a 10 mL bolus of 10% hypertonic saline was administered via the central venous catheter while EIT data were simultaneously recorded for another 3 minutes. This procedure was repeated at a PEEP of 15 cmH₂O. Pulmonary perfusion data were obtained through offline analysis of the EIT data.
Secondary	At PEEP 5 cmH₂O and 15 cmH₂O, perform EIT monitoring of pulmonary perfusion during a 15-second inspiratory or expiratory hold.	Under both PEEP 5 cmH₂O and PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	At a PEEP of 5 cmH₂O, EIT data were first recorded for 1 minute, followed by a 15-second inspiratory hold, after which data acquisition was continued for an additional 2 minutes. The entire procedure was repeated at a PEEP of 15 cmH₂O. Pulmonary perfusion data were subsequently analyzed using offline software.
Secondary	Under PEEP 5 cmH₂O conditions, EIT data were acquired during bolus injections of either 10 mL of 0.9% saline or 10 mL of 10% hypertonic saline for pulmonary perfusion analysis.	Under a PEEP of 5 cmH₂O, EIT data acquisition was performed after 30 minutes of stable ventilation.	At a PEEP of 5 cmH₂O, the following protocol was performed: First, EIT data were recorded for 1 minute, followed by a bolus injection of 10 mL of 0.9% saline via the central venous catheter; data acquisition then continued for an additional 2 minutes. Then, the procedure was repeated with a bolus injection of 10 mL of 10% hypertonic saline. Pulmonary perfusion data were subsequently analyzed using offline software.
Secondary	The ventilation-perfusion matching percentage was assessed using both pulse wave and saline bolus EIT at PEEP levels of 5 and 15 cmH₂O.	Under both PEEP 5 cmH₂O and PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	The ventilation-perfusion matching percentage was derived from EIT images using offline analysis software.
Secondary	The ventilation-perfusion matching percentage was monitored by EIT during 15-second inspiratory or expiratory holds at PEEP levels of 5 and 15 cmH₂O.	Under both PEEP 5 cmH₂O and PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	The ventilation-perfusion matching percentage was derived from EIT images using offline analysis software.
Secondary	Under PEEP 5 cmH₂O conditions, EIT data were acquired during bolus injections of either 10 mL of 0.9% saline or 10 mL of 10% hypertonic saline for ventilation-perfusion matching percentage.	Under a PEEP of 5 cmH₂O, EIT data acquisition was performed after 30 minutes of stable ventilation.	The ventilation-perfusion matching percentage was derived from EIT images using offline analysis software.
Secondary	The dead space percentage was assessed using both pulse wave and saline bolus EIT at PEEP levels of 5 and 15 cmH₂O.	Under both PEEP 5 cmH₂O and PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	The ventilation-perfusion matching percentage was derived from EIT images using offline analysis software.
Secondary	The dead space percentage was monitored by EIT during 15-second inspiratory or expiratory holds at PEEP levels of 5 and 15 cmH₂O.	Under both PEEP 5 cmH₂O and PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	The ventilation-perfusion matching percentage was derived from EIT images using offline analysis software.
Secondary	Under PEEP 5 cmH₂O conditions, the dead space percentage was obtained by EIT monitoring following bolus injections of either 10 mL of 0.9% saline or 10 mL of 10% hypertonic saline.	Under PEEP 5 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	The ventilation-perfusion matching percentage was derived from EIT images using offline analysis software.
Secondary	The shunt percentage was assessed using both pulse wave and saline bolus EIT at PEEP levels of 5 and 15 cmH₂O.	Under both PEEP 5 cmH₂O and PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	The ventilation-perfusion matching percentage was derived from EIT images using offline analysis software.
Secondary	The shunt space percentage was monitored by EIT during 15-second inspiratory or expiratory holds at PEEP levels of 5 and 15 cmH₂O.	Under both PEEP 5 cmH₂O and PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	The ventilation-perfusion matching percentage was derived from EIT images using offline analysis software.
Secondary	Under PEEP 5 cmH₂O conditions, the shunt space percentage was obtained by EIT monitoring following bolus injections of either 10 mL of 0.9% saline or 10 mL of 10% hypertonic saline.	Under PEEP 5 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	The ventilation-perfusion matching percentage was derived from EIT images using offline analysis software.
Secondary	At PEEP 5 cmH₂O, heart rate was monitored: at baseline, during 15-second inspiratory and expiratory holds, following bolus injections of 10 mL of 0.9% saline and 10% hypertonic saline, and during combined breath-hold-and-injection procedures.	Under PEEP 5 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	Heart rate was obtained from the patient monitor.
Secondary	At PEEP 15 cmH₂O, heart rate was monitored: at baseline, during 15-second inspiratory and expiratory holds, and during combined breath-hold-and-injection procedures.	Under PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	Heart rate was obtained from the patient monitor.
Secondary	At PEEP 5 cmH₂O, blood pressure was monitored: at baseline, during 15-second inspiratory and expiratory holds, following bolus injections of 10 mL of 0.9% saline and 10% hypertonic saline, and during combined breath-hold-and-injection procedures.	Under PEEP 5 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	Blood pressure was obtained from the patient monitor.
Secondary	At PEEP 15 cmH₂O, blood pressure was monitored: at baseline, during 15-second inspiratory and expiratory holds, and during combined breath-hold-and-injection procedures.	Under PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	Blood pressure was obtained from the patient monitor.
Secondary	At PEEP 5 cmH₂O, central venous pressure was monitored: at baseline, during 15-second inspiratory and expiratory holds, following bolus injections of 10 mL of 0.9% saline and 10% hypertonic saline, and during combined breath-hold-and-injection procedures	Under PEEP 5 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	Central venous pressure was obtained from the patient monitor.
Secondary	At PEEP 15 cmH₂O, central venous pressure was monitored: at baseline, during 15-second inspiratory and expiratory holds, and during combined breath-hold-and-injection procedures.	Under PEEP 15 cmH₂O conditions, EIT data were acquired after 30 minutes of stable ventilation.	Central venous pressure was obtained from the patient monitor.
Secondary	The PaO₂/FiO₂ ratio was recorded prior to patient enrollment.	Prior to enrollment	The PaO₂/FiO₂ ratio was obtained from arterial blood gas analysis.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07908368/registered

API reference For AI assistants